KRAS Mutation and NF-κB Activation Indicates Tolerance of Chemotherapy and Poor Prognosis in Colorectal Cancer
Digestive Diseases and Sciences, 05/18/2012
Lin G et al. – NF–κB activation was associated with KRAS mutation, and both KRAS mutation and NF–κB activation were indicative of high tolerance of chemotherapy and poor prognosis for colorectal cancer patients. Tumors with KRAS mutations and NF–κB activation may be a unique subtype of colorectal cancer.